Health Information Exchange Featured Article

September 04, 2012

Australia's Queensland Clinical Trials Biostatistics Center Selects OpenClinica Enterprise Software

The Clinical Trials and Biostatistics Center at Australia’s University of Queensland recently selected OpenClinica Enterprise software. It will provide electronic data capture and clinical data management.

“Given the diversity and complexity of our clinical studies, OpenClinica was a natural fit,” Sanjoy Paul, the center’s director, said in a press release. “It allows us to cost effectively undertake a wide range of projects on a robust, regulatory compliant data capture and data management system. We can standardize our expertise on a single platform while having greater control over building and managing studies.”

The Queensland Clinical Trials & Biostatistics Center (QCTBC) at the University of Queensland, founded in 2009, manages clinical studies and provides services for the design, protocol development, setup, database development, database management, statistical analysis and reporting of clinical trials for diverse diseases.

OpenClinica is commercial, open source software. It is Web-based. There are two editions: the OpenClinica Community Edition – which is freely available – and the OpenClinica Enterprise Edition – which is commercially supported.

“Our model provides inherent flexibility that makes it possible to operate more efficient, lower cost clinical studies, while meeting strict regulatory requirements,” Ben Baumann, co-founder and chief operating officer at OpenClinica, said in a statement carried by HealthTechZone.

The QCTBC is a center in the School of Population Health. It designs and conducts clinical trials, non-trial clinical studies and biostatistical research with both academic and industry partners.

The center is now studying cardio-metabolic effects of the new anti-diabetes drug (GLP-1R agonists), proteomics and metabolomics. The center is also studying a trial of Dose-Dense ABVD. It is an accelerated delivery of Adriamycin, Bleomycin, Vinblastin and Dacarbazine for patients with Hodgkin Lymphoma. Also, another trial is looking at treating prostate cancer using a Skyra 3T MRI machine located at Wesley Hospital.

In addition, the center provides consulting to clinical researchers and bio-pharmaceutical companies. 

Edited by Rich Steeves